Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellink_management.jpeg10601102Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-15 08:26:562021-02-15 08:26:56Cellink AB acquires Ginolis Oy for €70m
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.
https://european-biotechnology.com/wp-content/uploads/2024/04/Interna.jpg394768Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-09 14:07:332021-02-09 14:07:33InteRNA Technologies secures €18.5m in Series B financing
The German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
https://european-biotechnology.com/wp-content/uploads/2024/04/Jens_Spahn_Credits_BMG.jpg16531181Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-09 09:26:452021-02-09 09:26:45German Health Ministry to invest €6.2bn in vaccines
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
https://european-biotechnology.com/wp-content/uploads/2024/04/V-BIO.jpg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-07 17:35:452021-02-07 17:35:45V-Bio Ventures launches second fund at €78m
https://european-biotechnology.com/wp-content/uploads/2024/04/VC_money.jpg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-03 12:44:122021-02-03 12:44:12Abingworth raises US-$465m for new life sciences fund
https://european-biotechnology.com/wp-content/uploads/2024/04/Rentschler-Biopharma-headquarters.jpg7991200Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-02 06:00:572021-02-02 06:00:57Rentschler Biopharma to produce 100m doses of CureVac vaccine
Cellectis and Cytovia in US$760m licence deal
Latest NewsCell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
Higher omega-3 level apparently protects from dying from COVID-19
Sponsored PublicationsCellink AB acquires Ginolis Oy for €70m
Latest NewsCellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
Rentschler Biopharma launches gene therapy subsidiary
Latest NewsCDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
InteRNA Technologies secures €18.5m in Series B financing
Latest NewsMicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.
German Health Ministry to invest €6.2bn in vaccines
Latest NewsThe German Health Ministry has requested €6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
V-Bio Ventures launches second fund at €78m
Latest NewsV-Bio Ventures has announced the first closing of its V-Bio Fund 2 at €78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
Abingworth raises US-$465m for new life sciences fund
Latest NewsThe transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
Latest NewsAs rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
Rentschler Biopharma to produce 100m doses of CureVac vaccine
Latest NewsGerman CDMO Rentschler Biopharma is expanding cCMP production of CureVac NV’s RNA-based COVID-19 vaccine candidate CVnCoV.